Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone203-406-3700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.47 million
Profitability
Miscellaneous
Employees55
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions
What is Cara Therapeutics' stock symbol?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
How were Cara Therapeutics' earnings last quarter?
Cara Therapeutics Inc (NASDAQ:CARA) posted its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.03. The biopharmaceutical company earned $5.21 million during the quarter, compared to the consensus estimate of $5.14 million. Cara Therapeutics had a negative return on equity of 68.36% and a negative net margin of 420.97%. View Cara Therapeutics' Earnings History.
When is Cara Therapeutics' next earnings date?
What price target have analysts set for CARA?
9 analysts have issued 12 month price objectives for Cara Therapeutics' shares. Their predictions range from $13.36 to $39.00. On average, they expect Cara Therapeutics' share price to reach $26.9289 in the next twelve months. This suggests a possible upside of 15.3% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.
What is the consensus analysts' recommendation for Cara Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.
What are Wall Street analysts saying about Cara Therapeutics stock?
Here are some recent quotes from research analysts about Cara Therapeutics stock:
- 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (8/12/2019)
- 2. HC Wainwright analysts commented, "Our $28 price target (from $26) is based on an overall 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and further risk-discount oral Korsuva sales in Stage 3-5 CKD. The latter oral component’s $100M peak sales in our model reflects still a conservative 40% probability of success ($300M de-risked). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028." (5/29/2019)
Has Cara Therapeutics been receiving favorable news coverage?
Headlines about CARA stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cara Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Cara Therapeutics.
Who are some of Cara Therapeutics' key competitors?
Some companies that are related to Cara Therapeutics include Allakos (ALLK), FibroGen (FGEN), Alkermes (ALKS), Nektar Therapeutics (NKTR), United Therapeutics (UTHR), Evotec (EVTCY), Mirati Therapeutics (MRTX), Global Blood Therapeutics (GBT), Taro Pharmaceutical Industries (TARO), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM), Emergent Biosolutions (EBS), Genmab A/S (GMAB) and Ultragenyx Pharmaceutical (RARE).
What other stocks do shareholders of Cara Therapeutics own?
Who are Cara Therapeutics' key executives?
Cara Therapeutics' management team includes the folowing people:
- Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 55)
- Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 53)
- Dr. Joana Goncalves, Chief Medical Officer (Age 45)
- Dr. Joseph Stauffer, Consultant (Age 53)
- Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 67)
Who are Cara Therapeutics' major shareholders?
Cara Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include RHO Capital Partners Inc. (8.22%), BlackRock Inc. (7.21%), Price T Rowe Associates Inc. MD (7.04%), First Manhattan Co. (4.88%), Vanguard Group Inc. (4.48%) and ETF Managers Group LLC (2.40%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Institutional Ownership Trends for Cara Therapeutics.
Which institutional investors are selling Cara Therapeutics stock?
CARA stock was sold by a variety of institutional investors in the last quarter, including RHO Capital Partners Inc., Allianz Asset Management GmbH, Alps Advisors Inc., UBS Asset Management Americas Inc., Morgan Stanley, Cambridge Investment Research Advisors Inc., Advisor Group Inc. and Janney Montgomery Scott LLC. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View Insider Buying and Selling for Cara Therapeutics.
Which institutional investors are buying Cara Therapeutics stock?
CARA stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., ETF Managers Group LLC, Farallon Capital Management LLC, C WorldWide Group Holding A S, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, BlackRock Inc. and Wells Fargo & Company MN. View Insider Buying and Selling for Cara Therapeutics.
How do I buy shares of Cara Therapeutics?
Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cara Therapeutics' stock price today?
One share of CARA stock can currently be purchased for approximately $23.36.
How big of a company is Cara Therapeutics?
Cara Therapeutics has a market capitalization of $935.10 million and generates $13.47 million in revenue each year. The biopharmaceutical company earns $-74,010,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.View Additional Information About Cara Therapeutics.
What is Cara Therapeutics' official website?
How can I contact Cara Therapeutics?
Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.
MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
